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Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating, rapidly progressive disease leading to paralysis and death. Recently,
intermediate length polyglutamine (polyQ) repeats of 27–33 in ATAXIN-2 (ATXN2), encoding the ATXN2 protein, were found
to increase risk for ALS. In ATXN2, polyQ expansions of $34, which are pure CAG repeat expansions, cause spinocerebellar
ataxia type 2. However, similar length expansions that are interrupted with other codons, can present atypically with
parkinsonism, suggesting that configuration of the repeat sequence plays an important role in disease manifestation in
ATXN2 polyQ expansion diseases. Here we determined whether the expansions in ATXN2 associated with ALS were pure or
interrupted CAG repeats, and defined single nucleotide polymorphisms (SNPs) rs695871 and rs695872 in exon 1 of the gene,
to assess haplotype association. We found that the expanded repeat alleles of 40 ALS patients and 9 long-repeat length
controls were all interrupted, bearing 1–3 CAA codons within the CAG repeat. 21/21 expanded ALS chromosomes with
3CAA interruptions arose from one haplotype (GT), while 18/19 expanded ALS chromosomes with ,3CAA interruptions
arose from a different haplotype (CC). Moreover, age of disease onset was significantly earlier in patients bearing 3
interruptions vs fewer, and was distinct between haplotypes. These results indicate that CAG repeat expansions in ATXN2
associated with ALS are uniformly interrupted repeats and that the nature of the repeat sequence and haplotype, as well as
length of polyQ repeat, may play a role in the neurological effect conferred by expansions in ATXN2.
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Introduction
Amyotrophic lateral sclerosis (ALS, also referred to as Lou
Gehrig’s disease) is a progressive, fatal neurodegenerative disease
caused by the degeneration of motor neurons [1–3]. Approximately
10% of ALS cases are familial, with the remainder of cases being
sporadic. To date, 12 genetic loci have been identified associated
with familial ALS. Among these, mutations in superoxide dismutase
1( SOD1) account for 15–20% of cases of familial ALS [4]. Trans-
activate reponse DNA-binding protein (TARDBP, or TDP-43) is a
major disease protein of the ubiquitin-positive cytoplasmic inclu-
sions in ALS without SOD1 mutations [5]. Mutations in the TDP-
43 coding gene TARDBP were later found in multiple cases of
familial and sporadic ALS [6–9], indicating that TDP-43 plays a
critical role in disease pathogenesis.
Spinocerebellar ataxia 2 (SCA2) is an autosomal dominant
disease caused by an expanded CAG trinucleotide repeat
encoding glutamine within the open reading frame of the gene
encoding the ataxin 2 protein, ATAXIN2 (ATXN2) [10–12]. As
with other polyglutamine (polyQ) diseases, the length of the
CAG repeat expansion is inversely correlated with disease
onset and severity [13]. CAG repeats in normal alleles of
ATXN2 are variable in length, although by far the most
common allele carries 22 repeats. In the normal ATXN2 allele,
the CAG repeat region encoding the glutamine domain is
typically interrupted by one or more CAA repeats (also
encoding glutamine). The CAG repeat region within expanded
alleles of ATXN2 associated with SCA2 disease are 34–59 in
length [10–12,14–19]. Similar to other polyQ diseases, SCA2 is
for the most part a ‘‘pure’’ repeat disease. That is, the
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CAGs encoding glutamine. However, four years after the 1996
identification of expansions in ATXN2 as the molecular basis of
SCA2, a pathogenic length expansion bearing an ‘‘interrupt-
ed’’ repeat sequence was first reported [20]. It is now
recognized that lower-range polyQ repeat expansions in
ATXN2, of 33–49 in length, can be associated with levo-dopa
responsive parkinsonism [21–30]. Intriguingly, in the situations
of parkinsonism sequenced to date, the CAG repeat region has
been found to not be a pure CAG repeat run, but rather to be
interrupted with one or more CAA (or other) codons [21–30].
Additional data suggests that two SNPs (rs695871 and
rs695872) in exon 1 of the ATXN2 gene, where the CAG
repeat region occurs, predominant in distinct patterns in
normal versus SCA2 individuals: the GT haplotype predom-
inates in controls, whereas the CC haplotype is associated with
disease [19].
Recently, intermediate-length polyQ repeats in ATXN2 were
found to be a significant risk factor for ALS [31]. Consistent
with the association between ATXN2 and ALS, it was previously
known that SCA2 can present with motor neuron features that
mimic ALS [32,33]. Thus, it appears that individuals with
repeat expansions in ATXN2 can present with SCA2, parkin-
sonism, or ALS depending upon the length of the repeat.
Moreover, the finding that ATXN2-linked parkinsonism may be
associated with an interrupted CAG repeat region, versus the
pure CAG repeats typical of SCA2, raises the possibility that the
CAG purity of the repeat expansion may contribute to disease
manifestation.
Given these data, we sequenced the polyQ repeat region
within ATXN2 in the cases of ALS and controls harboring
A T X N 2p o l y Qr e p e a t so f2 7a n dh i g h e r[ 3 1 ] .O u rr e s u l t ss h o w
that the repeats associated with increased risk for ALS are
uniformly comprised of interrupted CAG repeats. All of the
sequences are interrupted by 1–3 CAA codons; none of the
repeats harbors a pure CAG repeat. Further, SNP analysis using
the derived cleaved amplified polymorphic sequences (dCAPS)
t e c h n i q u e[ 3 4 ]r e v e a l e dt h a tt he alleles with 3 CAA codons are
the GT haplotype, whereas alleles with fewer CAA codons are
predominantly the CC haplotype. Age of disease onset in
subjects with ALS and 3 CAA repeat interruptions, compared to
those with fewer, revealed that the age of onset was significantly
earlier; age of disease onset also differed by haplotype. This is
despite the fact that the average repeat length is shorter in
subjects with 3 CAA interruptions. These results highlight that
an interplay of the CAG repeat sequence configuration,
haplotype association, as well as repeat length, may play a
prominent role in disease manifestation in ATXN2-associated
neuropathologies.
Results
CAA interruptions in the CAG repeat region of ATXN2 in
ALS
We characterized the repeat sequence in 40 of the 45 ALS
cases with intermediate length polyQ repeats in the ATXN2 gene
of 27–33 in length and nine of the control cases [31]; these
constituted a subset of 40 ALS cases we previously reported with
expanded ATXN2 alleles for which motor neuron disease was the
initial presentation and from which we were able to obtain
amplifiable DNA. All 40 cases met El Escorial criteria for ALS; in
addition, for 19/40 cases (those from the University of
Pennsylvania Center for Neurodegenerative Disease Research
(CNDR)) clinical charts were available and reviewed by a
neurologist to confirm the diagnosis of ALS. With the exception
of one previously described individual with ataxic features late in
the course of disease (case A14, Table 1; [31]), these 19 well-
characterized cases did not demonstrate features atypical of ALS
such as parkinsonism or ataxia.
The ATXN2 repeat region was amplified by polymerase chain
reaction from genomic DNA samples. Because the repeats were
intermediate in length compared to the normal allele (22 or 23), it
was difficult to cleanly separate the allele bearing the longer repeat
from the normal allele. Thus, we were unable to sequence the
DNA directly from the PCR product and determine the sequence
with high integrity. Instead, the amplification products were
separated by size on a 4% agarose gel, then extracted, and
expanded alleles subcloned and sequenced. Multiple clones for
each allele were sequenced to assure against PCR-introduced
changes.
The length of the normal allele of the ALS patients was typically
22; this is consistent with previous findings that a repeat of 22 is
the most common normal allele [16,17,19,35]. For the longer
alleles, in ALS patients (n=40 with ATXN2 expansion), the
repeats ranged from 27 to 33, and in controls (n=9 with ATXN2
expansions) from 27 to 32. Sequencing of the repeat region
revealed that none of the polyQ repeats in patients with ALS were
comprised of pure CAG repeat expansions. Rather, all were
interrupted by at least 1 CAA codon, in stark contrast to the
situation observed in SCA2. Interruptions of the repeat sequence
are typical of the intermediate expansion repeats observed in
control individuals [19]. Note that such interruptions do not affect
the protein sequence, as CAA also encodes glutamine. Analysis of
the repeat length patterns indicated that the repeat region was
interrupted by 1, 2 or 3 CAA codons. Aside from the striking
finding that none of the repeats were pure CAG repeats, we also
observed among the Q27 repeats a monomorphic sequence
pattern of 3 CAA interruptions in an 8-4-4-8 configuration.
In order to determine whether or not the polyQ repeat sequence
was distinct among patients with repeat lengths within the ALS-
susceptibilityrange and controls, wealsosequenced9 neurologically
normal individuals with repeat lengths of 27 and longer (Table 2).
This analysis confirmed that the polyQ-encoding DNA sequence
was also interrupted in controls, and, moreover, bore interruption
patterns found among the ALS patients. Thus, the controls of 27
had the same repeat configuration as the ALS patients; there was
also no distinguishing feature among the controls with repeat
lengths of 29, 30 and 32—these DNAs showed interrupted repeat
patterns also found among ALSpatients. Taken together, thesedata
indicate that intermediate-length polyQ repeats in the ATXN2 gene
associated with ALS are CAA interrupted repeats bearing
interruptions of 1, 2 or 3 CAA codons.
Association of the haplotype of rs695871 and rs695872
with CAA interruptions in ATXN2
Two SNPs are found in exon 1 which bears the polyQ domain
of ATXN2. rs695871 is 177 bp upstream of the repeat, and bears
either a G or C base; the polymorphism affects the amino acid
sequence, changing a Val to a Leu. The second SNP rs695872 is a
T or C, and is silent, with no effect on the protein sequence.
Others have previously reported that these two SNPs define two
distinct haplotypes, a CC haplotype that appears to be
evolutionarily ancestral and a GT haplotype of more recent
origin; the CC haplotype predominates among SCA2 expanded
alleles [19,36]. Using dCAPS, to introduce a restriction enzyme
site depending upon the polymophism to allow the SNPs to be
defined by polymerase chain amplification followed by restriction
enzyme analysis [34], we defined these polymorphisms in the ALS
ATXN2 Repeats Associated with ALS Are Interrupted
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showed that the 1 and 2 CAA interruption situations were
predominantly associated with the CC haplotype (18/19 expand-
ed chromosomes), whereas the 3 CAA interrupted alleles were
uniformly the GT haplotype (21/21 chromosomes). This distinc-
tion was also the case for the intermediate length alleles among the
controls.
Association of the number of CAA interruptions and
haplotype in ATXN2 with age of disease onset among the
ALS patients
We considered whether the number of CAA interruptions
within the repeat region and/or the genetic background in the
form of SNP haplotype might result in differences in disease
Table 1. Sequence of the polyQ repeat region of expanded allele of ALS patients.
Case ID
Expanded
allele Age at Onset CAG Pattern
SNP expanded
allele** CAA# Pattern
A32 29 49 20-8 CC 1 OOOOOOOOOOOOOOOOOOOONOOOOOOOO
A48 29 72 20-8 CC 1 OOOOOOOOOOOOOOOOOOOONOOOOOOOO
A35 30 62 21-8 CC 1 OOOOOOOOOOOOOOOOOOOOONOOOOOOOO
A33 30 72 21-8 CC 1 OOOOOOOOOOOOOOOOOOOOONOOOOOOOO
A42 31 74 21-9 CC 1 OOOOOOOOOOOOOOOOOOOOONOOOOOOOOO
A37 31 61 21-9 CC 1 OOOOOOOOOOOOOOOOOOOOONOOOOOOOOO
A43 31 58 22-8 CC 1 OOOOOOOOOOOOOOOOOOOOOONOOOOOOOO
A50 32 77 22-9 CC 1 OOOOOOOOOOOOOOOOOOOOOONOOOOOOOOO
A47 32 79 23-8 CC 1 OOOOOOOOOOOOOOOOOOOOOOONOOOOOOOO
A51 32 55 23-8 CC 1 OOOOOOOOOOOOOOOOOOOOOOONOOOOOOOO
A49 32 53 23-8 CC 1 OOOOOOOOOOOOOOOOOOOOOOONOOOOOOOO
A53 33 52 23-9 CC 1 OOOOOOOOOOOOOOOOOOOOOOONOOOOOOOOO
A52 33 70 23-9 CC 1 OOOOOOOOOOOOOOOOOOOOOOONOOOOOOOOO
A30 28 55 13-5-8 CC 2 OOOOOOOOOOOOONOOOOONOOOOOOOO
A41* 29 35 13-6-8 CC 2 OOOOOOOOOOOOONOOOOOONOOOOOOOO
A34 30 58 13-7-8 CC 2 OOOOOOOOOOOOONOOOOOOONOOOOOOOO
A38 31 56 8-13-8 GT 2 OOOOOOOONOOOOOOOOOOOOONOOOOOOOO
A40 31 65 13-7-9 CC 2 OOOOOOOOOOOOONOOOOOOONOOOOOOOOO
A45 32 54 13-8-9 CC 2 OOOOOOOOOOOOONOOOOOOOONOOOOOOOOO
A14 27 30 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A17* 27 65 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A16 27 not known 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A18 27 53 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A19 27 59 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A20 27 57 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A21 27 60 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A22 27 46 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A23 27 49 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A24 27 53 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A12 27 66 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A25 27 48 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A27 27 51 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A26 27 47 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A28 27 62 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A10 27 51 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A11 27 61 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A13 27 59 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
A31 29 64 8-4-4-10 GT 3 OOOOOOOONOOOONOOOONOOOOOOOOOO
A39 31 63 8-4-8-8 GT 3 OOOOOOOONOOOONOOOOOOOONOOOOOOOO
A46 32 42 8-4-9-8 GT 3 OOOOOOOONOOOONOOOOOOOOONOOOOOOOO
*familial situation,
**SNP695871 SNP695872.
doi:10.1371/journal.pone.0017951.t001
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onset, disease duration (for postmortem cases, n=15), gender and
presence/absence of atypical features differed by number of CAA
interruptions or SNP haplotype. We found that age at onset
among the ALS patients differed significantly depending on the
number of CAA interruptions and the haplotype in the expanded
allele, with individuals with more CAA interruptions and of the
GT haplotype developing disease earlier (Figure 2, number of
interruptions p-value for trend=0.01, 3CAA vs ,3CAA HR 1.9;
haplotype, p=0.03; log rank test). This is despite the fact that ALS
patients with 3CAA interruptions have a shorter average repeat
length (27.5) versus patients with fewer interruptions (30.8).
Normally, for polyQ repeat expansion diseases, the relationship
between repeat length and disease onset is such that longer repeats
are associated with an earlier age of disease onset [13,37]; thus,
this trend for an earlier age of disease onset does not correlate with
average repeat length. Other clinical features, such as gender,
disease duration, presence/absence of atypical features, did not
differ among the groups.
Discussion
Multiple faces of ATXN2 in neurological disease
PolyQ expansions in ATXN2 are now associated with three
clinically distinct neurological diseases; these different situations are
associated with different repeat lengths and sequence configuration
of the DNA repeat region (Figure 3). If the polyQ domain within
ATXN2 is composed of a pure CAG repeat with a length $34, this
presents with SCA2 [10–12,14–19]. However, repeat expansions in
ATXN2 can also present with levo-dopa responsive parkinsonism;
about half of these situations have been sequenced. The repeat
lengths range from 33 to 49, and in the situations sequenced, the
polyQ domain is not a pure CAG repeat run, but rather is
comprised of an interrupted CAG repeat region [22–30]. Further,
recent studies indicate that intermediate-length polyQ repeats in
ATXN2 of 27 to 33 are associated with increased risk for ALS [31],
although the precise repeat length cut-off is likely to vary depending
uponthepopulation[38].Hereweshowthat ALS-associated polyQ
repeats in ATXN2 are uniformly interrupted CAG repeats,
comprised of interruptions of 1–3 CAA codons. We also observed
a haplotype distinction between individuals bearing 3CAA
interruptions and fewer. Note that CAA also encodes glutamine,
thus the repeat region within the protein will remain a pure polyQ
domain. These data suggest that the length of the polyQ repeat, as
well as the CAG-repeat purity of the repeat region and the
haplotype, influence disease presentation.
RNA toxicity in ATXN2-related neuropathology
That interrupted and uninterrupted polyQ repeat expansions
with similar length in ATXN2 lead to different neurological
presentations (SCA2 or parkinsonism) highlights the possibility
that repeat sequence configuration, as well as repeat length, is an
important arbiter in clinical manifestation and phenotypic
variability in ATXN2-associated pathologies. SCA2 is known to
show nigral atrophy and motor neuron loss; that is, the clinical
manifestations of parkinsonism and motor neuron disease are
within the spectrum of SCA2 pathology [39–41]. Intriguingly,
select situations appear biased strongly toward one neurological
outcome or another; interestingly, this may be influenced by not
only the length of the repeat, but also the purity of the CAG repeat
region encoding the polyQ expansion.
Table 2. Sequence of the polyQ repeat region of expanded alleles of controls.
Case ID
Atx2
length
Age at
sampling CAG Pattern SNP expanded allele CAA # Pattern
N11 27 80 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
N12 27 65 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
N13 27 62 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
N14 27 61 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
N15 27 74 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
N16 27 73 8-4-4-8 GT 3 OOOOOOOONOOOONOOOONOOOOOOOO
N22 29 59 8-4-4-10 GT 3 OOOOOOOONOOOONOOOONOOOOOOOOOO
N23 30 57 21-8 CC 1 OOOOOOOOOOOOOOOOOOOOONOOOOOOOO
N24 32 59 13-8-9 CC 2 OOOOOOOOOOOOONOOOOOOOONOOOOOOOOO
**SNP695871 SNP695872.
doi:10.1371/journal.pone.0017951.t002
Figure 1. SNP analysis by dCAPS method. Analysis of restriction
fragments for SNP (A) rs695871 and (B) rs695872. For SNP rs695871 (C
or G, AvaII digestion) analysis of a Q32/Q22 patient, the amplified
products were Q32:359bp and Q22:329bp. If Q32 is linked to a C, AvaII
will digest the product into two fragments of 313 bp and 46 bp. If Q32
is linked to a G, AvaII will not cut. If Q22 is linked to a C, AvaII will digest
it into fragments of 46 bp and 283 bp. If Q22 is linked to a G, AvaII will
not cut. In the case of C/G heterozygotes, some uncut hybrid product
remained. For SNP rs695872 (C or T, NotI digestion) analysis of a Q32/
Q22 patient, the amplified products were Q32:308bp and Q22:278bp. If
Q32 is linked to a C, NotI will digest the product into two fragments of
254 bp and 64 bp. If Q32 is linked to a T, NotI will not cut. If Q22 is
linked to a C, NotI will digest it into fragments of 64 bp and 214 bp. If
Q22 is linked to a T, NotI will not cut. In the case of C/T heterozygotes,
some uncut hybrid product remained. In the gels, the low molecular
weight bands (46, 64 bp) are largely undetectable; the pattern is scored
by whether the higher bands are cut or not.
doi:10.1371/journal.pone.0017951.g001
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disease, with dominant toxicity conferred by the expanded polyQ
domain [13,37]. However, some data suggest that the situation may
be more complicated, and that pathogenic mechanisms beyond
toxicity or abnormal interactions solely due to the polyQ-containing
protein may contribute to polyQ expansion diseases. For example,
toxicity at the level of the expanded repeat RNA is conferred by
CAG expansions in Drosophila [42], C elegans and mammals [43,44].
Notably, CAA interruptions within the repeat sequence for SCA3
shift the toxicity curve, such that expression of a polyQ protein of
identical amino acid sequence, but encoded by a CAA/G
interrupted repeat region, is less toxic [42]. In the context of
human disease, interruptions may present with different manifes-
tations, or different clinical features of disease being dominant. In
potential support of this idea, interruption of the CAG repeat
expansion by a CAT codon within the ATXN1 polyQ-encoding
domain was reported to cause later onset and milder disease in a
rare case of SCA1 compared to pure, uninterrupted repeats of
similar length [45]. An intriguing situation also occurs in SCA17,
which is due to polyQ repeat expansions in TATA-box binding
protein (TBP) [46–48]. Normally, the polyQ repeat region within
TBP is interrupted by multiple CAA codons, and remains so in the
expanded disease situation. Intriguingly, the threshold for a
pathogenic repeat length is higher for repeat expansions for
SCA17 (,44) compared to that of most of the dominantly inherited
spinocerebellar ataxias (,37) [13,49]. It is tempting to speculate
that this shifted toxicity curve for SCA17 may be due to the
interrupted repeat sequence of the polyQ domain within TBP.
Our findings are consistent with the idea that both the presence
of any CAA interruptions and the presence of increasing numbers
of CAA interruptions may influence phenotypic presentation.
Specifically, while the overwhelming majority of SCA patients
have pure CAG repeat expansions [10–12,37,41], 40/40 ALS
patients in this study had at least one CAA interruption. Among
these 40 patients with CAA interruptions, the number of
interruptions as well as the haplotype may matter. Here we found
an earlier age at onset for those ALS patients with more
interruptions and who also share the GT haplotype.
The 3CAA-interrupted chromosomes arose on one genetic
background (the GT haplotype), and most ,3CAA-interrupted
chromosomes arose on a different genetic background (the CC
haplotype). We found both an association between earlier age at
onset and number of CAA interruptions as well as SNP haplotype.
Moreover, the fact that the ALS patients are not associated with a
single haplotype may explain why ATXN2 has not emerged as a
significant contributor to ALS from genome wide association
(GWA) studies [50–53]. Intriguingly, however, a SNP linked to a
gene that interacts with ATXN2, Ataxin-2 binding protein, has
been identified as significant [50,54]. Our previous study found an
earlierageofdiseaseonset inasmallcohortofALSpatients(n=65),
when comparing those bearing a longer ATXN2 repeat to those
with a normal length repeat [31]; it is possible that those data were
driven by patients with 3CAA interruptions in the repeat sequence,
of the GT haplotype. As with all such findings, such trends require
confirmation among larger and additional sets of patients.
How might the sequence within the repeat region influence
disease presentation? Whether the repeat sequence is a pure CAG
or an interrupted CAG is predicted to influence somatic instability
of the repeat, with a pure repeat being far more unstable and
tending to expand [19,55–57]. CAA interruptions have been
Figure 2. Age of disease onset by repeat interruptions and
haplotype. Age of disease onset by (A) repeat interruptions or by (B)
haplotype for ALS patients bearing either 3CAA interruptions within the
polyQ repeat region, versus patients with fewer than 3 CAA
interruptions. The patients with 3 interruptions show an earlier disease
onset, with a hazard ratio (HR) of 1.9, compared to patients with fewer
interruptions. This is despite that patients with 3 CAA interruptions
have an average repeat length that is lower (27.5) compared to patients
with fewer interruptions (30.8). The age of disease onset is also
significantly different when broken down by haplotype.
doi:10.1371/journal.pone.0017951.g002
Figure 3. The spectrum of diseases associated with ATXN2 polyQ repeat expansions. Although the repeat in ATXN2 is polymorphic
normally, it is typically 22. In this cohort of controls, we found that only 1.4% (12/980 total) had repeats greater than 27 (range 27–31), whereas 4.7%
of this cohort of ALS patients [31] had repeats of 27–33 (43/915 sporadic, 3/65 familial); the exact cut-off associated with risk for ALS may vary in
different populations [38]. The repeats of ALS and high range controls from this study are interrupted by 1–3 CAA codons. ATXN2 repeats associated
with parkinsonism range from 34 to 49, and studies to date indicate that the repeats are interrupted [21,27]. Repeat expansions associated with SCA2
are greater than 34, and are typically pure CAG repeats [12,14,37].
doi:10.1371/journal.pone.0017951.g003
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repeat in ATXN2, with their absence predisposing ATXN2 alleles
towards instability and pathogenic expansion to SCA2 disease
[19]. Interruptions in a CAG repeat RNA by CAA codons are
predicted to affect the secondary structure [58]. Even the
interruption of a single CAA codon can have a notable effect on
structure and free energy of folding. Moreover, if, as with other
expanded repeat RNAs such as CGG expanded RNA of FXTAS
[59,60] and expanded CTG repeats of myotonic dystrophy [61],
the CAG repeat RNA interacts with select proteins, the altered
structure due to CAA interruptions may result in differential
interactions. Such differential protein or other interactions may in
part contribute to the distinct disease manifestations. The purity of
the repeat may also influence the level of the mRNA and/or level
of the translated protein. Such an influence of the RNA may be
notable for ALS, as defects in RNA processing and metabolism
may particularly relevant. The association of mutations in TDP43
and fused in sarcoma (FUS)/translocated in liposarcoma (TLS),
two RNA-binding proteins with striking structural and functional
similarities [62], as well as ATXN2, which itself is an RNA binding
protein, in ALS [31], suggests a prominent role for RNA binding
proteins and RNA-dependent processes in the disease.
Methods
Ethics statement
Samples from the CNDR were obtained with written informed
consent under Institutional Board Approval of the University of
Pennsylvania. Samples from Coriell were obtained with permis-
sion from the Coriell Institute for Medical Research Institutional
Review Board. The individual submitters who contributed DNA
samples to Coriell received written informed consent from all
patients (or guardians of patients) participating in the study
(consent for research).
PolyQ repeat amplification and sequencing
The polyglutamine repeat region of the ATXN2 gene was
amplified from genomic DNA isolated from B-lymphocytes of
controls and ALS patients. Patient samples were from the CNDR
(19/40 ALS samples with 27 or more repeats) and Coriell (21/40
ALS samples with 27 or more repeats), controls were from Coriell;
for additional details see [31]. Amplification was carried out with
the primers SCA2-S2 (59-CGCCGCGTTCCGGCGTCTCC-39)
and SCA2-B (59-CGGGCTTGCGGACATTGG-39), using Ta-
kara LA taq with GC buffer (Takara RR02AG, Shiga, Japan) plus
5% DMSO (Sigma, Cat# D8779). The amplification products
were separated on a 4% agarose gel, purified, then sub-cloned into
the pGEMT Easy vector (Promega Cat.# A1360, Madison,
Wisconsin) and transformed into DH5alpha competent cells
(Invitrogen Cat. #18265017, Carlsbad, CA). Colonies were
screened by amplification to identify those bearing the expanded
allele. For each expanded allele, 2–6 clones from at least two
independent PCR reactions were prepared by Qiagen mini-prep
and sequenced using the T7 primer from the pGEMT Easy
vector.
SNP genotyping
The dCAPS technique [34] was used to analyze SNP rs695871
and SNP rs695872 (www.ncbi.nlm.nih.gov/SNP/) within exon1 of
the human ATXN2 gene. For SNP695871, Primer SCA2-AVAII
(59-ctcccggcggctccttggtctcggcggg CCTCCCCGCCCCTTCGT-
GGTC-39, mismatch underlined) was used such that one
mismatch was introduced to generate a recognition site for the
restriction endonuclease AvaII (recognition site 59-G9G(A/T)CC-
39). Products covering the SNP and polyQ repeat region were
amplified with primers SCA2-AVAII and SCA2-B (59-
CGGGCTTGCGGACATTGG-39) using LA taq DNA polymer-
ase as above. Undigested and AvaII-digested products were
separated on a 4% agarose gel in parallel. AvaII could only cut the
amplified product if the SNP were a C and not a G. Thus, the
SNP (C or G) and linkage to the normal or expanded allele were
determined by the digestion pattern. For SNP695872, Primer
SCA2-NOTI (59-ccttctccccctcgccagcccgggcgcccctccggccgcgccaa-
cccgcg CCTCCCCGCTCGGCGGCCG-39, mismatch under-
lined) was used such that one mismatch was introduced to
generate a recognition site for the restriction endonuclease NotI
(recognition site 59-GC9GGCCGC-39). Products spanning the
SNP and polyQ region were amplified with primers SCA2-NOTI
and SCA2-B. Undigested and NotI-digested products were
separated on a 4% agarose gel in parallel. NotI could only cut
the amplified product if the SNP were a C and not T. Thus, the
SNP (C or T) and the linkage to the normal or expanded allele
were determined by the digestion pattern.
Statistics
Survival curve analyses using log-rank tests were used to
compare age at onset, disease duration, gender, and presence/
absence of atypical features between subgroups of ALS patients
with 1,2 and 3CAA interruptions, and between subgroups of ALS
patients with different genetic backgrounds.
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